A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of BI655130 (SPESOLIMAB) Induction Therapy in Patients With Moderate-to-severely Active Ulcerative Colitis Who Have Failed Previous Biologics Therapy
Phase of Trial: Phase II/III
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Spesolimab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 19 Aug 2019 Planned End Date changed from 30 May 2021 to 30 May 2022.
- 19 Aug 2019 Planned primary completion date changed from 2 May 2021 to 2 May 2022.
- 18 Feb 2019 Planned primary completion date changed from 23 Mar 2021 to 2 May 2021.